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Strategic Plan 2021 – 2025
Delivering for patients through collaborative 
health product regulation
This Strategic Plan sets out our ambition for 
the next five years to deliver better outcomes 
for people and animals through value-driven 
regulation and partnerships.
Building on our partnerships with others is a key 
theme of this five-year strategy. The twin challenges 
of Brexit and Covid-19 have demonstrated the need 
for, and value of, working collaboratively across 
Europe and internationally, with the health system in 
Ireland, and with patients and the public. Working 
with national agencies, professional bodies and 
patient groups can help us regulate more effectively 
taking into account the needs of the health system, 
while our input into relevant parts of the system can 
influence the safe use of health products in clinical 
practice. The pandemic has also highlighted the 
importance of the interconnectedness of the health 
of people, animals, plants and the environment, 
known as the One Health concept. 
Patients are the users of medicines, devices and 
health products and our most important stakeholder 
group. Regulators are increasingly mindful that 
the views of the public and patients must be  
incorporated into the regulatory process. While we 
have taken forward specific initiatives over recent 
years, we are committed through this plan to 
building greater engagement with patients which we 
believe will contribute to broader-based and better-
informed regulatory decisions.
Major legislative changes will occur over the next five 
years, with the implementation of EU Regulations 
on clinical trials, veterinary medicines, medical 
devices and in-vitro diagnostics, and each Regulation 
will impact significantly on the operation of the 
relevant regulatory system. For the HPRA, these 
constitute major projects which require contribution 
to national legislation, extensive engagement with 
all stakeholders, and development of information 
resources for those affected by the legislation.
We are living in a time in which public demand 
for information is increasing, and numerous, 
sometimes unreliable, information sources exist. 
Conflicting information and multiple channels 
of communication can undermine the critical 
importance of the regulatory system. We will 
maintain a focus on increasing understanding of the 
work we do, being transparent around decision-
making, communicating via suitable channels in a 
timely manner, and identifying and appropriately 
managing emerging risks.
Scientific and technological innovation has 
accelerated dramatically in recent years with 
advances in personalised medicines, convergence of 
health products with digital information, and novel 
manufacturing technologies. Innovative products 
can greatly improve patient outcomes but may pose 
challenges to the current regulatory system as well as 
create the need for appropriate supports. Working 
together with European and international partners,  
we will contribute to more timely and consistent 
approaches to regulating innovative products. We 
will also need to develop the necessary expertise to 
regulate effectively in a digitised environment.
The Strategy has been developed in a highly 
collaborative way, involving all staff and the 
members of the Authority and the statutory advisory 
committees. A public consultation provided 
feedback from many stakeholders to help guide the 
development of the plan. We would like to thank 
all those who took the time and effort to make 
submissions which have been taken into account in 
the preparation of this plan.
Implementation will require a high level of 
commitment and effort from everyone, enabled 
by continuing development of our people, ways of 
working and a digital transformation programme. 
Key targets will be included in the Performance 
Delivery Agreement with the Department of Health. 
Detailed activities will be planned and delivered 
through the annual business planning cycle, and 
implementation monitored through reporting to 
senior management and the Authority.
We look forward to working with the Authority, 
the advisory committee members and our staff 
in delivering on this strategy in a time of some 
uncertainty but great potential for enhancing the 
value of health product regulation for people, 
animals and the healthcare system.
Ann Horan Lorraine Nolan
Chairperson Chief executive
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Introduction
What we regulate
We inspect companies and 
facilities which test, make  
or distribute health products 
to ensure that they comply 
with relevant standards and 
legislation
We grant licences to 
companies to make, 
distribute and market 
medicines after a review 
of their safety, quality and 
effectiveness
We continuously monitor 
medicines, medical devices 
and other health products, 
responding quickly to any 
safety or quality concerns
We produce safety and 
quality information to 
support the safe use of 
health products
How we regulate




















Excellence in health product 
regulation through science, 
collaboration and innovation
We regulate medicines  
and devices for the benefit 
of people and animals
Excellence




We believe in the power  
of diversity, where 
everyone is equal
Collaboration
We work with others  
in partnership, respect  
and trust
Innovation
We continually learn,  
adapt and improve
Patient focused
We put the interests of 
those who use health  
products first
Integrity
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Our mission, vision and values
Our strategy 






































Enhance the role 
of the HPRA as 
a partner and 
contributor within 
the health system, 
to optimise safe 
and effective use of 
health products 
Enhance national 
systems to better 
regulate animal 









of risk based 
approaches to 
regulation









































Increasing our use of 
proportionate and 
adaptive approaches 





our models of 
engagement 
to strengthen 










Goal 4Goal 3Goal 2Goal 1
Develop and empower our people to achieve and succeed
Improve organisation effectiveness through extended and enhanced use of digital technologies
Create better ways of working for the organisation, its stakeholders and the environment
Ensure financial stability and capacity to meet the future needs of the organisation
Great people, great processes
Developing our organisation and people to 
successfully achieve our goals






across all areas 
of the health 
system
Goal 1







Improve preparedness for significant 
change, threats and crises impacting in 
health product regulation and availability.
Formalised mechanisms and systems with 
regulatory and health system partners 
provide greater responsiveness, continuity 
and resilience.
Collaborate with government, the health 
system and other stakeholders to manage 
the regulation and availability of health 
products post Brexit.
The impact of Brexit on availability of health 
products is minimised and measures are in 
place that strengthen integration with other 
European markets.
Collaborate nationally and internationally 
on the regulation and surveillance of 
medicines, medical devices, diagnostics 
and vaccines for Covid-19.
Covid-19 diagnostics, therapeutics and 
vaccines used in Ireland are robustly 
regulated and monitored, with up-to-date 
information provided to all stakeholders.
Contribute to One Health initiatives 
including antimicrobial resistance and 
impacts of health products on the 
environment.
Improved understanding of wider impacts 
of health products, and actions taken to 
reduce adverse effects.
1.2 Enhance 
the role of 
the HPRA as 









Strengthen systems for exchange of 
information and reporting on health 
products between health system partners, 
healthcare professionals, members of the 
public and the HPRA.
Better quality and diversity of data enhance 
monitoring and surveillance over the 
lifecycle of a health product.
Leverage collaborative efforts to promote 
and support system-wide responses to 
important health product issues.
Engagement across stakeholders enables 
cohesive and coordinated responses to 
important health product issues.
Enhance understanding of how important 
regulatory action is best embedded 
and implemented into clinical practice 
nationally.
Approaches developed to evaluate the 
impact and effectiveness of significant 
regulatory action at national level.
Contribute to the implementation of the 
Sláintecare programme for healthcare 
delivery.
Health system developments informed and 
enhanced by regulatory requirements for 
health products.
Support the continued development of the 
clinical research infrastructure in Ireland.
Clinical researchers have access to 
integrated supports and a streamlined 









Embed the application of 3R principles in 
animal-based research in Ireland.
Projects and clinical trials conducted in 
Ireland meet international best practice in 
3Rs.
Strengthen the pharmacovigilance system 
through new methods and tools for 
promotion and analysis of reports and 
dissemination of safety information to 
healthcare professionals and animal owners.
The pharmacovigilance system is more 
responsive and effective, with increased 
reporting by healthcare professionals and 
animal owners.
Goal 1: Health system partnerships
Strengthening our collaborations across all areas of the health system
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Progressive 
regulation

















Develop stakeholder partnerships to 
support implementation of new legislation 
for medical devices, clinical trials and 
veterinary medicines.
Implementation delivers value to all 
stakeholders, reduces regulatory burden 
where appropriate, while ensuring 
protection for the users of health products.
Promote European network approaches, 
expertise development and mutual 
reliance among regulators in line with new 
requirements.
Strengthened cooperation across the 
EU regulatory network with measurable 
impacts.
Influence the development of national 
legislation to enhance standards and 
regulation.
Gaps in regulatory approaches and areas 







Further develop internal capabilities to 
identify areas of risk through greater use of 
intelligence sources.
Increased organisational competency 
in risk and risk management principles. 
Intelligence sources identified for proactive 
management of emerging risks.
Adapt assessment, compliance monitoring 
and enforcement approaches in line with 
identified risks.
Risk-based strategies increase use of 
proactive approaches, and reduce the level 
of non-compliance.
Enhance focus on lifecycle management in 
our regulatory approach.
Demonstrated use of data-driven, risk- 
adaptive approaches to support regulatory 
decisions pre and post approval.




Promote greater use of mutual reliance 
among global regulators.
Demonstrated influence on the European 
and international networks’ strategic 
objectives on mutual reliance.
Drive the development of greater 
international convergence and 
harmonisation on regulatory standards.
Active participation and contribution in 
relevant international committees and 
projects.
Promote greater communication of risk 
and intelligence sharing among global 
regulators.
Demonstrated influence on the 
establishment of infrastructure to support 
intelligence sharing among global 
regulators.
Goal 2: Progressive regulation
Increasing our use of proportionate and adaptive approaches for better 
patient outcomes




our models of 
engagement 
to strengthen 
public trust and 
confidence
Goal 3








Develop new engagement and 
communications strategies in consultation 
with stakeholders.
Stakeholder analysis is regularly conducted, 
their views are valued and taken into 
account across corporate and regulatory 
activities.
Use the voices of patients and the public to 
inform our regulatory and safety monitoring 
programmes.
Demonstrable proactive partnership model 
based on listening, understanding and 
communicating with the public.
Establish a greater level of ongoing 
engagement with healthcare professionals 
and their representative bodies.
Engagement with healthcare professionals 
contributes to greater patient safety and 
optimal use of health products.
3.2 Strengthen 







Promote awareness and understanding of 
the HPRA’s role in protecting the health of 
people and animals.
Greater public profile of the agency and 
perception of trust in health product 
regulation.
Increase proactive publishing of clear, 
relevant and understandable information.
Additional information and data sets 
published, with greater transparency 
around the evaluation process.
Incorporate current best practices in 
communicating science and risk.
Improved ability to communicate in clear 







Develop our website as a key 
communication tool for interacting with 
stakeholders and an authoritative source of 
reliable regulatory information.
Communications with stakeholders 
integrated into organisational processes. 
Timely website content in plain language, 
accessible in formats appropriate to the 
different stakeholder groups.
Increase use of social media and other 
communication methods including 
traditional and non-media where 
appropriate.
Increased reach and diversity of content 
across different audiences and channels, 
supporting key safety messaging.
Contribute to educational programmes for 
key target groups.
A range of resources is available for 
patients, and for healthcare professionals 
and researchers at relevant points in their 
careers.
Goal 3: Communication and engagement
Improving our models of engagement to strengthen public trust and 
confidence










Objectives Specific actions Outcomes





Actively contribute to EU and international 
horizon-scanning initiatives.
The regulatory system is well positioned 
to respond to the dynamic life sciences 
environment.
Support regulatory science tools and 
approaches that effectively respond to 
scientific and technological innovation.
Novel therapies and technologies are 
effectively regulated while facilitating safe 
and timely access.
Promote cooperation and integration 
between regulatory networks and 
frameworks to facilitate harmonisation and 
avoid duplication.
Regulatory standards and guidance provide 








Work with national partners to use existing 
networks to raise awareness of regulatory 
supports among Irish life sciences 
researchers.
Established mechanisms in place for 
systematic outreach to relevant research 
communities.
Provide advice and guidance for researchers 
that can be accessed throughout the 
development cycle.
Regular use by researchers of regulatory 
and scientific advice provided by the HPRA 
or the European regulatory system.
Engage with Irish researchers and 
developers to identify mechanisms and 
support initiatives that facilitate the 
translation of research into clinical practice.
Input from researchers informs the 
development of new or improved 
regulatory supports. Irish researchers 






Develop and implement a strategy that 
identifies key areas of innovation for 
organisational specialisation.
A programme of activities for competence 
development in focus areas relevant to 
patients, the research community and the 
life sciences sector in Ireland.
Develop knowledge and skills to regulate 
in a digitised environment encompassing 
regulatory processes, products, 
manufacturing, wholesaling, and healthcare 
delivery.
Capabilities contribute to and keep pace 
with the advances in digitisation in the 
regulatory environment.
Engage with EU regulatory network to 
maximise contribution of key expertise.
Increased levels of advice provided within 
areas of specific expertise.
Goal 4: Enabling innovation
Enhancing our supports for innovation from discovery through to 
regulatory approval









Objectives Specific actions Outcomes
5.1 Develop 
and empower 
our people to 
achieve and 
succeed
Design and implement a new people 
strategy.
An organisation-wide strategy based on 
developing the skills and competencies 
needed to ensure a resilient, evolving 
workplace.
An enhanced employee experience and 
wellbeing at work.
Values based, purposeful working.
Define key areas of expertise and future 
skills needs.
Agreed development pathways to access 
key skills, e.g. training programmes, 
recruitment, contract workers.
Enhance leadership capability to manage 
the organisation through change and 
growth.
A resilient organisation, flexible, responsive 








use of digital 
technologies
Consolidate case management onto a 
single, optimised platform. Enhance data 
quality and decision support capabilities.
Streamlined operational processes 
and analytics. Reduced complexity of 
technology environment.
Extend digital integration with stakeholders, 
providing integration with core applications.
Enhanced engagement with stakeholders 
and contribution to the national health 
system. Improved integration with the 
European regulatory network.
Improve performance and resilience of 
the technology infrastructure. Enhance the 
security of the digital infrastructure.
Improved technology risk profile and 
enhanced operational flexibility. Reduced 










Define the optimal organisational design to 
support delivery of our remit now and into 
the future.
A sustainable organisational structure 
underpinned by a robust succession plan 
and people strategy.
Develop models of working that meet the 
changing environment and future of work.
Flexible approaches to support 
performance and productivity conducive to 
an adaptive model of working.
Improve cross-organisational 
methodologies for better management of 
capacity and organisational performance.
Balanced resource utilisation, consistency of 
processes, and enhanced use of expertise 
across different functional areas.
Continue to take actions that sustain more 
environmentally friendly practices.
Government targets for public sector 
energy efficiency are met, staff encouraged 
to reduce their own energy usage and 
CO2 emissions, and goods purchased 
reflect environmental considerations where 
possible.
Ensure ongoing compliance with the public 
sector equality and human rights duty.
Equality of opportunity and treatment 
for staff, stakeholders and those we 
communicate and interact with.
Goal 5: Great people, great processes
Developing our organisation and people to successfully achieve our goals
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needs of the 
organisation
Update financial and fee modelling to take 
account of the changing environment for 
the organisation and for regulated sectors.
Stable financial systems allowing 
management of the organisation in a 
steady state and with ongoing changes in 
the external environment.
Conduct a structured review of the use of 
the infrastructure and utilisation plans to 
reflect the new paradigms of working.
Sustainable and efficient use of resources 
including the building.
Goal 5
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